Taptica International Ltd (LON:TAP) Stock Rating Reiterated by Berenberg; The GBX 600.00 Target Indicates 37.14% Potential; 2 Analysts Covering Orexigen Therapeutics, Inc. (OREX)

Taptica International Ltd (LON:TAP) had its stock rating noted as Buy by analysts at Berenberg. Berenberg currently has a GBX 600.00 PT on the 274.17M GBP market cap company or 37.14% upside potential. This was revealed in an analyst report on Monday, 22 January.

Among 5 analysts covering Orexigen Therapeutics (NASDAQ:OREX), 2 have Buy rating, 1 Sell and 2 Hold. Therefore 40% are positive. Orexigen Therapeutics has $21 highest and $2 lowest target. $6.60’s average target is 464.10% above currents $1.17 stock price. Orexigen Therapeutics had 12 analyst reports since August 5, 2015 according to SRatingsIntel. As per Friday, November 6, the company rating was maintained by RBC Capital Markets. The company was reinitiated on Friday, December 11 by Bank of America. The firm earned “Market Perform” rating on Wednesday, March 16 by JMP Securities. The stock has “Overweight” rating by Piper Jaffray on Tuesday, October 6. As per Friday, December 4, the company rating was downgraded by Wells Fargo. The company was upgraded on Wednesday, August 5 by Zacks. The stock of Orexigen Therapeutics, Inc. (NASDAQ:OREX) has “” rating given on Tuesday, September 15 by RBC Capital Markets. The stock of Orexigen Therapeutics, Inc. (NASDAQ:OREX) has “Buy” rating given on Saturday, August 8 by Piper Jaffray. JP Morgan maintained Orexigen Therapeutics, Inc. (NASDAQ:OREX) on Monday, August 10 with “Buy” rating. See Orexigen Therapeutics, Inc. (NASDAQ:OREX) latest ratings:

The stock decreased 1.24% or GBX 5.5 during the last trading session, reaching GBX 439.5. About 76,405 shares traded. Taptica International Ltd (LON:TAP) has 0.00% since January 22, 2017 and is . It has underperformed by 16.70% the S&P500.

Since August 3, 2017, it had 0 buys, and 1 sale for $1.58 million activity. $1.58M worth of Taptica International Ltd (LON:TAP) was sold by Hattersley Gavin.

Investors sentiment increased to 1.18 in Q3 2017. Its up 0.28, from 0.9 in 2017Q2. It increased, as 48 investors sold Taptica International Ltd shares while 137 reduced holdings. 67 funds opened positions while 152 raised stakes. 161.22 million shares or 2.19% less from 164.83 million shares in 2017Q2 were reported. Interocean Capital Limited Liability Company reported 131,064 shares. Mason Street Ltd Liability Company invested 0.05% in Taptica International Ltd (LON:TAP). Pnc Fin Grp reported 0% in Taptica International Ltd (LON:TAP). Amica Mutual invested 0.07% in Taptica International Ltd (LON:TAP). Smithfield invested in 2,410 shares or 0.03% of the stock. Tdam Usa has invested 0.45% in Taptica International Ltd (LON:TAP). Motco owns 330 shares. Moreover, Putnam Investments Limited Liability has 0.17% invested in Taptica International Ltd (LON:TAP) for 918,427 shares. Great West Life Assurance Can has invested 0.03% in Taptica International Ltd (LON:TAP). Oregon Employees Retirement Fund holds 0.03% or 19,741 shares. Charter Trust accumulated 5,291 shares or 0.05% of the stock. Moreover, Hsbc Holdg Public Limited Company has 0.02% invested in Taptica International Ltd (LON:TAP). Arlington Value Capital Ltd Liability holds 1.73% or 211,632 shares in its portfolio. Atria Investments Lc holds 2,992 shares or 0.01% of its portfolio. State Of Wisconsin Investment Board holds 204,835 shares.

Taptica International Ltd., together with its subsidiaries, operates a mobile advertising platform. The company has market cap of 274.17 million GBP. The firm offers data-focused marketing solutions that drive execution and brand insight on mobile by leveraging video, social, native, and display to reach the users for various applications, services, and brands. It has a 14.46 P/E ratio. It primarily serves companies and brands in Israel, the United States, China, Germany, the United Kingdom, and internationally.

Among 3 analysts covering Taptica International Ltd Ord Nis0.01 Di (LON:TAP), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Taptica International Ltd Ord Nis0.01 Di has GBX 600 highest and GBX 90 lowest target. GBX 447.33’s average target is 1.78% above currents GBX 439.5 stock price. Taptica International Ltd Ord Nis0.01 Di had 17 analyst reports since September 25, 2015 according to SRatingsIntel. The stock has “Buy” rating by Investec on Thursday, October 15. Investec maintained the shares of TAP in report on Monday, January 11 with “Buy” rating. FinnCap maintained Taptica International Ltd (LON:TAP) on Thursday, November 9 with “Corporate” rating. The stock of Taptica International Ltd (LON:TAP) has “Buy” rating given on Thursday, January 5 by Investec. The rating was maintained by FinnCap with “Corporate” on Thursday, January 4. FinnCap maintained Taptica International Ltd (LON:TAP) rating on Friday, January 19. FinnCap has “Corporate” rating and GBX 550 target. Investec maintained Taptica International Ltd (LON:TAP) on Wednesday, January 13 with “Buy” rating. The stock of Taptica International Ltd (LON:TAP) has “Corporate” rating given on Tuesday, September 26 by FinnCap. The firm has “Buy” rating given on Wednesday, July 19 by Berenberg. The stock of Taptica International Ltd (LON:TAP) has “Buy” rating given on Monday, January 22 by Berenberg.

Analysts await Taptica International Ltd (LON:TAP) to report earnings on February, 13. They expect $0.59 earnings per share, up 28.26% or $0.13 from last year’s $0.46 per share. TAP’s profit will be $368,053 for 186.23 P/E if the $0.59 EPS becomes a reality. After $1.34 actual earnings per share reported by Taptica International Ltd for the previous quarter, Wall Street now forecasts -55.97% negative EPS growth.

Orexigen Therapeutics, Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products primarily in the United States, Europe, and South Korea. The company has market cap of $19.43 million. It offers Contrave for the treatment of obesity. It currently has negative earnings. The firm also offers Contrave under the Mysimba brand name.